Q-omics provides the consensus-scored ANKRD33 profile across patient tissues and cancer cell-line models. ANKRD33 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ANKRD33 is differentially expressed in 12, with the highest sampling consensus in LUSC. Additionally, ANKRD33 RNA expression shows 8,608 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LUSC, and THYM as cancer lineages where ANKRD33 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD33 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD33 survival associations across molecular data types. ANKRD33 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD33 RNA expression–survival associations across cancer types. High ANKRD33 expression shows unfavorable associations in KIRC, STAD, UCEC, UVM, KIRP and KICH. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ANKRD33 RNA expression.
This table summarizes ANKRD33 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for ANKRD33. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD33 shows lower tumor expression in BRCA and higher tumor expression in LUSC, COAD, LIHC, KIRC and READ. The LUSC box plot shows higher ANKRD33 RNA expression in tumor versus normal tissue (log2 FC = +0.094, t-test p = .007).
This table shows molecular features associated with ANKRD33 in patient tissues and cancer cell lines. In patient samples, ANKRD33 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD33 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and PANCREAS.
